硬脂醇衍生物修饰脂质体及其小鼠肝靶向性的药物分析研究  

Study on Stearyl Alcohol Derivatives Modified Liposome and Mouse Liver Targeting Drug Analysis

作　　者：孙圣峰[1] 郭伟英[1] 陈莹[1] 吴阳[1] 

机构地区：[1]辽宁医学院,辽宁锦州121001

出　　处：《辽宁医学院学报》2010年第5期393-396,426,共5页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：目的制备硬脂醇衍生物修饰脂质体并考察其肝靶向性及药物分析。方法合成硬脂醇-O-半乳糖苷(18-Gal)导向分子修饰索拉非尼(Sorafenib tosylate,ST)并制备脂质体(GDSL),考察其包封率和粒径的指标:取小鼠分别尾静脉注射GDSL和ST水溶液,通过测定给药后各组织中ST的浓度计算GDSL的肝靶向指数(TI)。结果所制GDSL包封率为65.85%,粒径(203±11)nm,肝组织的TI值为4.745。结论所制GDSL包封率较高,肝靶向性明显。Objective To prepare stearyl alcohol derivatives modified liposome and to investigate its liver targeting and drug analysis.Methods The encapsulation efficiency and the size of the indicators were found by the synthesis of stearic alcohol-O-galactosidase（18-Gal） driven molecular modification Sorafenib（Sorafenib tosylate,ST） and the preparation of liposome（GDSL）.Mice were taken to do intravenous injection of GDSL and ST solution.GDSL liver targeting index（TI） was calculated by measuring the concentration of various tissues ST.Results The encapsulation efficiency of GDSL system was 65.85%.Particle size was（203±11）nm.TI value of the liver tissue was 4.745.Conclusions The encapsulation efficiency of GDSL system is high and liver targeting is significant.

关 键 词：硬脂醇 D-半乳糖 索拉非尼 脂质体 

分 类 号：R917[医药卫生—药物分析学]